Delivery of the active substance mirvetuximab soravtansine used in the drug program B.50 for the tr

Tender Notice

Tender Detail
Delivery of the active substance mirvetuximab soravtansine used in the drug program B.50 for the treatment of patients with ovarian cancer
Tendering Authority
Tender Category
Other
Publish Date
29 May 2026
Deadline
12 Jun 2026
Country
Poland
TenderNews Ref. No.
2824616260529-0
Document Fees
Refer Document.
EMD
Refer Document.
Tender Value
PLN 6466000
« Previous Tender      Next Tender »

Some of Our Valuable Clients